Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. - sprookjes - yvandenbroek - TriplyDB

Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.

Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.

http://www.wikidata.org/entity/Q33614767

about

Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis.Pathogenesis of nonmelanoma skin cancers in organ transplant recipients Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway The complexities of TGF-β action during mammary and squamous cell carcinogenesis.Post-transplant malignancy: reducing the risk in kidney transplant recipients.Targeting TGF-β Signaling for Therapeutic Gain.The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients.Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma.

P2860

Q33728014-780B0226-7428-4579-8482-5CD2981BC2AE Q34713840-A2A3D788-192E-466A-BC5C-A1648A15D483 Q34984571-5A9F66D6-A8FA-4775-8CEA-0F068036D463 Q36462328-B507030E-54B2-445A-8688-2333AF5E0738 Q37863680-6FA51353-EDFD-4AA5-BA39-242CD5C8126B Q39155151-0E253653-0B89-4037-B1DA-0DDCE79EEADA Q46271884-1D51F30B-D8CF-492C-BED7-3FF5F1E87CC5 Q51734226-8F3B30AE-AD2C-4B31-A8EC-173C6C759245

P2860

Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.

http://www.wikidata.org/entity/Q33614767

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Elevated cutaneous Smad activa ...... n organ transplant recipients.

@ast

Elevated cutaneous Smad activa ...... n organ transplant recipients.

@en

type

label

Elevated cutaneous Smad activa ...... n organ transplant recipients.

@ast

Elevated cutaneous Smad activa ...... n organ transplant recipients.

@en

prefLabel

Elevated cutaneous Smad activa ...... n organ transplant recipients.

@ast

Elevated cutaneous Smad activa ...... n organ transplant recipients.

@en

P1433

Q33614767-72B7DAB0-ADF2-4C6F-A4B9-5C3F9C9E720E

P1476

Q33614767-FCD835F0-AB35-4058-A9C8-497A9B0610CE

P2093

Q33614767-31FC1048-7078-4E2C-BDA0-68658C65C528

Q33614767-3C08380C-EC03-45C8-B8CF-1DF837FCA4DE

Q33614767-76C1926E-51BB-4E6E-919C-1EB2D5AA0473

Q33614767-785E4D6E-7B4A-4A00-BD6D-5B1495CDF407

Q33614767-7FF44B4B-EA2C-4C3C-BEBC-D759E5F6220A

Q33614767-B47FC6F8-90AC-457F-87DC-1FDFA1D0F5B1

Q33614767-C3B6498F-9D55-44B9-B20E-ABA121803F49

Q33614767-CE20743E-1CB3-4511-9240-1B88EDE9ABC3

Q33614767-E50BF1B9-C8E5-4B21-95BB-494A7D73F6D9

P2860

Q33614767-10EA0CE2-33D7-4D57-B82E-045DC4C98C22

Q33614767-13418506-EF15-4326-9848-EE703DC2DB90

Q33614767-190EE50B-A50C-4C4A-B629-54FE8ACE3215

Q33614767-1C0084B9-6EC1-4426-9CC2-823567B43999

Q33614767-277D14F1-E9C8-47EA-A427-C8A1D00D3FDC

Q33614767-2CCB8DD7-1ADD-4045-B6F1-564F9FE45EDB

Q33614767-2D132B80-1B73-4B3D-89FA-FE17F3714193

Q33614767-3D49C91C-F181-4DF4-B483-A660E56A06E4

Q33614767-4922BFDE-64EB-4DAF-A59D-B0A97DBDDAA1

Q33614767-5514A8CD-89BC-4488-8EB0-B0878F38E4F6

P304

Q33614767-6ABE7CD7-B47F-4EE5-9B49-7E2241526660

P31

Q33614767-2C3C7987-A93E-40DC-B8F0-5184CDE975B5

P356

Q33614767-4D16F794-44FA-45F6-B361-5272D1F79607

P407

Q33614767-3893CCDA-FC1C-47AA-898C-37698B24D784

P433

Q33614767-4B746B67-642D-4603-88D3-4E1EA2E20A35

P478

Q33614767-16F15A08-C0C8-4D62-9614-9E5D8DD28FE2

P577

Q33614767-AA060E0D-5818-4B99-8013-1A2C9D6854B1

P5875

Q33614767-189417EC-4FA6-483F-9FB8-8F3CFFE9A3CE

P698

Q33614767-025EAE71-A129-4502-88EA-984CCAEADAAB

P932

Q33614767-260DEAE2-9B72-4D23-9C03-389D397DF942

P356

1078-0432.CCR-08-3286

P1433

Clinical Cancer Research

P1476

Elevated cutaneous Smad activa ...... n organ transplant recipients.

@en

P2093

Boris C Bastian

http://www.w3.org/2001/XMLSchema#string

Dan H Moore

http://www.w3.org/2001/XMLSchema#string

Elise F Saunier

http://www.w3.org/2001/XMLSchema#string

Ervin H Epstein

http://www.w3.org/2001/XMLSchema#string

Frederic F Clermont

http://www.w3.org/2001/XMLSchema#string

Jesus Perez-Losada

http://www.w3.org/2001/XMLSchema#string

Katie Ridd

http://www.w3.org/2001/XMLSchema#string

Kelly A Harradine

http://www.w3.org/2001/XMLSchema#string

Rosemary J Akhurst

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

NFATc1 balances quiescence and proliferation of skin stem cells

Reversible Smad-dependent signaling between tumor suppression and oncogenesis

TGF-beta signaling in tumor suppression and cancer progression

Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.

Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.

TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility.

Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration

P304

5101-5107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-3286

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26733369

http://www.w3.org/2001/XMLSchema#string

P698

19671862

http://www.w3.org/2001/XMLSchema#string

P932

2812428

http://www.w3.org/2001/XMLSchema#string